- Home
- MTR vs JAGX Comparison
MTR vs JAGX Comparison
Compare MTR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- JAGX
- Stock Information
- Founded
- MTR 1979
- JAGX 2013
- Country
- MTR United States
- JAGX United States
- Employees
- MTR N/A
- JAGX N/A
- Industry
- MTR Oil & Gas Production
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- JAGX Health Care
- Exchange
- MTR Nasdaq
- JAGX Nasdaq
- Market Cap
- MTR 11.7M
- JAGX 12.9M
- IPO Year
- MTR N/A
- JAGX N/A
- Fundamental
- Price
- MTR $6.26
- JAGX $0.46
- Analyst Decision
- MTR
- JAGX
- Analyst Count
- MTR 0
- JAGX 0
- Target Price
- MTR N/A
- JAGX N/A
- AVG Volume (30 Days)
- MTR 3.8K
- JAGX 382.2K
- Earning Date
- MTR 01-01-0001
- JAGX 03-31-2025
- Dividend Yield
- MTR 2.86%
- JAGX N/A
- EPS Growth
- MTR N/A
- JAGX N/A
- EPS
- MTR 0.35
- JAGX N/A
- Revenue
- MTR $966,169.00
- JAGX $10,480,000.00
- Revenue This Year
- MTR N/A
- JAGX $18.18
- Revenue Next Year
- MTR N/A
- JAGX $40.06
- P/E Ratio
- MTR $18.31
- JAGX N/A
- Revenue Growth
- MTR N/A
- JAGX N/A
- 52 Week Low
- MTR $5.60
- JAGX $0.46
- 52 Week High
- MTR $11.99
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- MTR 51.57
- JAGX 28.37
- Support Level
- MTR $6.18
- JAGX $0.46
- Resistance Level
- MTR $6.54
- JAGX $0.60
- Average True Range (ATR)
- MTR 0.08
- JAGX 0.06
- MACD
- MTR 0.03
- JAGX -0.02
- Stochastic Oscillator
- MTR 61.11
- JAGX 6.03
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.